BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/14/2019 6:53:01 AM | Browse: 150 | Download: 105
Publication Name World Journal of Gastroenterology
Manuscript ID 46112
Country of Manuscript Source Netherlands
2019-01-29 02:39
Peer-Review Started
2019-01-29 04:32
To Make the First Decision
2019-03-27 05:44
Return for Revision
2019-03-27 07:24
2019-03-28 12:32
Second Decision
2019-04-19 07:10
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-04-20 02:04
Articles in Press
2019-04-20 02:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-05-29 02:18
Publish the Manuscript Online
2019-06-06 08:31
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript type Opinion Review
Article Title Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics
Manuscript Source Invited Manuscript
All Author List Michiel Dirk Voskuil, Amber Bangma, Rinse Karel Weersma and Eleonora Anna Margaretha Festen
Funding Agency and Grant Number
Correspondence To Michiel Dirk Voskuil, MD, Research Fellow, Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, PO Box 30001, Hanzeplein 1, Groningen 9713 GZ, Netherlands. m.d.voskuil@umcg.nl
Keywords Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Pharmacogenetics; Personalized medicine
Core Tip In recent years, strong pharmacogenetic associations for drugs used in the management of inflammatory bowel disease (IBD) have been identified. However, the implementation of pre-treatment pharmacogenetic testing into clinical guidelines has been challenging. Particular groups of patients are needlessly exposed to (expensive) drugs that are either ineffective or harmful. Pre-treatment screening for TPMT and NUDT15 genetic variation should be incorporated into clinical IBD management guidelines. Therapeutic recommendations based on HLA genetic variants, conferring risk for thiopurine-induced pancreatitis and immunogenicity to tumor necrosis factor-antagonists, respectively, should be further evaluated.
Publish Date 2019-06-06 08:31
Citation Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics. World J Gastroenterol 2019; 25(21): 2539-2548
Url https://www.wjgnet.com/1007-9327/full/v25/i21/2539.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i21.2539
Full Article (PDF) WJG-25-2539.pdf
Full Article (Word) WJG-25-2539.docx
Manuscript File 46112-Review.docx
Answering Reviewers 46112-Answering reviewers.pdf
Audio Core Tip 46112-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 46112-Conflict-of-interest statement.pdf
Copyright License Agreement 46112-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 46112-Language certificate.pdf
Peer-review Report 46112-Peer-review(s).pdf
Scientific Misconduct Check 46112-Scientific misconduct check.pdf
Scientific Editor Work List 46112-Scientific editor work list.pdf